The PDX models showed that treatment with sh-UBE2C resulted in significant reductions in tumor volume compared with tumor volumes in the control group (Figure 7, B–D), indicating that silencing UBE2C had a therapeutic effect on the progression of BCa. This evidence concerns the gene UBE2C and neoplasm.